{
  "slug": "rhodiola",
  "name": "Rhodiola Rosea",
  "alternate_names": [
    "Rhodiola rosea",
    "Rosenroot",
    "Golden root",
    "Arctic root",
    "Salidroside",
    "Rosavin",
    "SHR-5"
  ],
  "mechanism": [
    "HPA-axis modulation / cortisol-response normalization (adaptogen research model)",
    "AMPK pathway activation (preclinical anti-fatigue hypothesis)",
    "Monoamine oxidase modulation (preclinical)",
    "NRF2 / antioxidant-response activation (preclinical)"
  ],
  "target": [
    "HPA axis / cortisol response",
    "AMPK energy-sensing pathway",
    "Monoamine turnover (MAO)",
    "NRF2 / oxidative-stress markers"
  ],
  "use_case": [
    "stress-related fatigue (research-context)",
    "subjective stress / burnout symptom scores (research-context)",
    "endurance / exercise performance (research-context)"
  ],
  "body_system": [
    "MOOD",
    "NEURO",
    "MUSCULO",
    "ENDO"
  ],
  "evidence_tier": "B",
  "evidence_anchor_pmid_count": 3,
  "dosage_range": "200-600 mg/day standardized root extract (typ. >=3% rosavins + >=1% salidroside; SHR-5 clinical extract at 288-576 mg/day; acute exercise studies used 200 mg ~1 h pre-exercise). Educational reference, not a dosing instruction.",
  "safety_notes": "Generally well tolerated in clinical trials at typical doses (200-600 mg/day) with no serious adverse events in studied populations. Not pregnancy/lactation safety-established; theoretical caution with antidepressant/MAO-active or stimulant medications. Note R. rosea differs chemically from R. crenulata (crenulata lacks rosavin), and some cited preclinical work used crenulata.",
  "regulatory": {
    "fda": "Botanical dietary supplement under DSHEA (Rhodiola rosea root extract); structure/function claims only (adaptogen/stress/energy support); no FDA-approved disease/health claim",
    "efsa": "No authorized Reg 432/2012 Art.13 health claim; an EMA/HMPC traditional-use herbal monograph exists; marketable in the EU via Traditional Herbal Registration (traditional-use wording only)",
    "anvisa": "Not listed on ANVISA approved-plant / IN 28/2018 constituent lists; no authorized functional claim; would require case-by-case new-ingredient assessment"
  },
  "authorized_claims": [],
  "ingredient_hub_url": "https://asxan.ai/ingredients/rhodiola/",
  "related_goal_slugs": [
    "cognitive-support"
  ],
  "related_lifestyle_slugs": [
    "high-stress",
    "athletic-performance"
  ],
  "last_evidence_review": "2026-06-13",
  "schema_version": "nc-public-v0.2",
  "api_version": "nc-public-v0.3",
  "_meta": {
    "last_evidence_review": "2026-06-13",
    "ip_axes_disclosed": {
      "public_axes": [
        "mechanism",
        "target",
        "use_case",
        "body_system",
        "evidence_tier",
        "dosage_range",
        "safety_notes",
        "regulatory",
        "authorized_claims"
      ],
      "ip_axes_not_exposed": [
        "proprietary_formula_ratios",
        "clinical_protocol_internals",
        "rnd_pipeline_compounds",
        "supplier_specific_grade_specifications",
        "unpublished_endpoint_data"
      ],
      "rationale": "asxan.ai surfaces the educational, evidence-tier-disclosed slice. Formula composition, clinical-protocol internals, and RnD pipeline data are intentionally outside this public surface."
    }
  }
}